- Standort
-
Deutsche Nationalbibliothek Frankfurt am Main
- ISSN
-
1179-6901
- Umfang
-
Online-Ressource
- Sprache
-
Englisch
- Anmerkungen
-
online resource.
- Erschienen in
-
Dosing Considerations for Antibodies Against COVID-19 ; day:1 ; month:12 ; year:2020 ; pages:1-8
Drugs in R & D ; (1.12.2020), 1-8
- Urheber
-
Tegenge, Million A.
Mahmood, Iftekhar
Struble, Evi
Golding, Basil
- Beteiligte Personen und Organisationen
-
SpringerLink (Online service)
- DOI
-
10.1007/s40268-020-00330-3
- URN
-
urn:nbn:de:101:1-2021011018555162904619
- Rechteinformation
-
Open Access; Der Zugriff auf das Objekt ist unbeschränkt möglich.
- Letzte Aktualisierung
- 15.08.2025, 05:24 UTC
Datenpartner
Dieses Objekt wird bereitgestellt von:
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Deutsche Nationalbibliothek. Bei Fragen zum Objekt wenden Sie sich bitte an den Datenpartner.
Beteiligte
- Tegenge, Million A.
- Mahmood, Iftekhar
- Struble, Evi
- Golding, Basil
- SpringerLink (Online service)
Ähnliche Objekte (12)
Neonatal Therapeutics: Considerations for Dosing
Digoxin-specific antibodies: a novel dosing strategy
Defining neutralization and allostery by antibodies against COVID-19 variants
Individualized Dosing of Therapeutic Monoclonal Antibodies—a Changing Treatment Paradigm?
Prevalence of antibodies against COVID-19 in the staff of a COVID-19 regular ward
Potent and broadly neutralizing antibodies against sarbecoviruses induced by sequential COVID-19 vaccination
Natural and engineered antibodies against HIV
Recombinant antibodies against viral interleukin 6
Antibodies against P. falciparum glycosylphosphatidylinositol epitopes
Recombinant antibodies against viral interleukin 6
Drug dosing in hospitalized obese patients with COVID-19
Target-Mediated Drug Disposition Model for Bispecific Antibodies : Properties, Approximation and Optimal Dosing Strategy
Neonatal Therapeutics: Considerations for Dosing
Digoxin-specific antibodies: a novel dosing strategy
Defining neutralization and allostery by antibodies against COVID-19 variants
Individualized Dosing of Therapeutic Monoclonal Antibodies—a Changing Treatment Paradigm?
Prevalence of antibodies against COVID-19 in the staff of a COVID-19 regular ward
Potent and broadly neutralizing antibodies against sarbecoviruses induced by sequential COVID-19 vaccination
Natural and engineered antibodies against HIV
Recombinant antibodies against viral interleukin 6
Antibodies against P. falciparum glycosylphosphatidylinositol epitopes
Recombinant antibodies against viral interleukin 6
Drug dosing in hospitalized obese patients with COVID-19
Target-Mediated Drug Disposition Model for Bispecific Antibodies : Properties, Approximation and Optimal Dosing Strategy
Neonatal Therapeutics: Considerations for Dosing
Digoxin-specific antibodies: a novel dosing strategy
Defining neutralization and allostery by antibodies against COVID-19 variants
Individualized Dosing of Therapeutic Monoclonal Antibodies—a Changing Treatment Paradigm?
Prevalence of antibodies against COVID-19 in the staff of a COVID-19 regular ward
Potent and broadly neutralizing antibodies against sarbecoviruses induced by sequential COVID-19 vaccination
Natural and engineered antibodies against HIV
Recombinant antibodies against viral interleukin 6
Antibodies against P. falciparum glycosylphosphatidylinositol epitopes
Recombinant antibodies against viral interleukin 6
Drug dosing in hospitalized obese patients with COVID-19